BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 25605372)

  • 1. MOZ regulates B-cell progenitors and, consequently, Moz haploinsufficiency dramatically retards MYC-induced lymphoma development.
    Sheikh BN; Lee SC; El-Saafin F; Vanyai HK; Hu Y; Pang SH; Grabow S; Strasser A; Nutt SL; Alexander WS; Smyth GK; Voss AK; Thomas T
    Blood; 2015 Mar; 125(12):1910-21. PubMed ID: 25605372
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MOZ is critical for the development of MOZ/MLL fusion-induced leukemia through regulation of Hoxa9/Meis1 expression.
    Katsumoto T; Ogawara Y; Yamagata K; Aikawa Y; Goitsuka R; Nakamura T; Kitabayashi I
    Blood Adv; 2022 Oct; 6(19):5527-5537. PubMed ID: 35947126
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bromodomain-PHD finger protein 1 is critical for leukemogenesis associated with MOZ-TIF2 fusion.
    Shima H; Yamagata K; Aikawa Y; Shino M; Koseki H; Shimada H; Kitabayashi I
    Int J Hematol; 2014 Jan; 99(1):21-31. PubMed ID: 24258712
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibitors of histone acetyltransferases KAT6A/B induce senescence and arrest tumour growth.
    Baell JB; Leaver DJ; Hermans SJ; Kelly GL; Brennan MS; Downer NL; Nguyen N; Wichmann J; McRae HM; Yang Y; Cleary B; Lagiakos HR; Mieruszynski S; Pacini G; Vanyai HK; Bergamasco MI; May RE; Davey BK; Morgan KJ; Sealey AJ; Wang B; Zamudio N; Wilcox S; Garnham AL; Sheikh BN; Aubrey BJ; Doggett K; Chung MC; de Silva M; Bentley J; Pilling P; Hattarki M; Dolezal O; Dennis ML; Falk H; Ren B; Charman SA; White KL; Rautela J; Newbold A; Hawkins ED; Johnstone RW; Huntington ND; Peat TS; Heath JK; Strasser A; Parker MW; Smyth GK; Street IP; Monahan BJ; Voss AK; Thomas T
    Nature; 2018 Aug; 560(7717):253-257. PubMed ID: 30069049
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MOZ is essential for maintenance of hematopoietic stem cells.
    Katsumoto T; Aikawa Y; Iwama A; Ueda S; Ichikawa H; Ochiya T; Kitabayashi I
    Genes Dev; 2006 May; 20(10):1321-30. PubMed ID: 16702405
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of the MOZ-TIF2 oncoprotein in mice represses senescence.
    Largeot A; Perez-Campo FM; Marinopoulou E; Lie-a-Ling M; Kouskoff V; Lacaud G
    Exp Hematol; 2016 Apr; 44(4):231-7.e4. PubMed ID: 26854485
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MOZ-TIF2 inhibits transcription by nuclear receptors and p53 by impairment of CBP function.
    Kindle KB; Troke PJ; Collins HM; Matsuda S; Bossi D; Bellodi C; Kalkhoven E; Salomoni P; Pelicci PG; Minucci S; Heery DM
    Mol Cell Biol; 2005 Feb; 25(3):988-1002. PubMed ID: 15657427
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Roles of the histone acetyltransferase monocytic leukemia zinc finger protein in normal and malignant hematopoiesis.
    Katsumoto T; Yoshida N; Kitabayashi I
    Cancer Sci; 2008 Aug; 99(8):1523-7. PubMed ID: 18754862
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A MOZ-TIF2 leukemia mouse model displays KAT6-dependent H3K23 propionylation and overexpression of a set of active developmental genes.
    Smolko AE; Sullivan DW; Olsen SN; Kang H; Whedon SD; Baell JB; Cole PA; Armstrong SA; Kuroda MI
    Proc Natl Acad Sci U S A; 2024 Jun; 121(26):e2405905121. PubMed ID: 38889153
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MOZ-TIF2 alters cofactor recruitment and histone modification at the RARbeta2 promoter: differential effects of MOZ fusion proteins on CBP- and MOZ-dependent activators.
    Collins HM; Kindle KB; Matsuda S; Ryan C; Troke PJF; Kalkhoven E; Heery DM
    J Biol Chem; 2006 Jun; 281(25):17124-17133. PubMed ID: 16613851
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MOZ (MYST3, KAT6A) inhibits senescence via the INK4A-ARF pathway.
    Sheikh BN; Phipson B; El-Saafin F; Vanyai HK; Downer NL; Bird MJ; Kueh AJ; May RE; Smyth GK; Voss AK; Thomas T
    Oncogene; 2015 Nov; 34(47):5807-20. PubMed ID: 25772242
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MOZ increases p53 acetylation and premature senescence through its complex formation with PML.
    Rokudai S; Laptenko O; Arnal SM; Taya Y; Kitabayashi I; Prives C
    Proc Natl Acad Sci U S A; 2013 Mar; 110(10):3895-900. PubMed ID: 23431171
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MOZ fusion proteins in acute myeloid leukaemia.
    Troke PJ; Kindle KB; Collins HM; Heery DM
    Biochem Soc Symp; 2006; (73):23-39. PubMed ID: 16626284
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [FGFR1 and MOZ, two key genes involved in malignant hemopathies linked to rearrangements within the chromosomal region 8p11-12].
    Pébusque MJ; Chaffanet M; Popovici C; Birnbaum D
    Bull Cancer; 2000 Dec; 87(12):887-94. PubMed ID: 11174118
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Symplekin, a polyadenylation factor, prevents MOZ and MLL activity on HOXA9 in hematopoietic cells.
    Largeot A; Paggetti J; Broséus J; Aucagne R; Lagrange B; Martin RZ; Berthelet J; Quéré R; Lucchi G; Ducoroy P; Bastie JN; Delva L
    Biochim Biophys Acta; 2013 Dec; 1833(12):3054-3063. PubMed ID: 23994619
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MOZ and BMI1 act synergistically to maintain hematopoietic stem cells.
    Sheikh BN; Metcalf D; Voss AK; Thomas T
    Exp Hematol; 2017 Mar; 47():83-97.e8. PubMed ID: 27773671
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acute mixed lineage leukemia with an inv(8)(p11q13) resulting in fusion of the genes for MOZ and TIF2.
    Liang J; Prouty L; Williams BJ; Dayton MA; Blanchard KL
    Blood; 1998 Sep; 92(6):2118-22. PubMed ID: 9731070
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Monocytic leukemia zinc finger protein is essential for the development of long-term reconstituting hematopoietic stem cells.
    Thomas T; Corcoran LM; Gugasyan R; Dixon MP; Brodnicki T; Nutt SL; Metcalf D; Voss AK
    Genes Dev; 2006 May; 20(9):1175-86. PubMed ID: 16651658
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The histone acetyl transferase activity of monocytic leukemia zinc finger is critical for the proliferation of hematopoietic precursors.
    Perez-Campo FM; Borrow J; Kouskoff V; Lacaud G
    Blood; 2009 May; 113(20):4866-74. PubMed ID: 19264921
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined loss of PUMA and p21 accelerates c-MYC-driven lymphoma development considerably less than loss of one allele of p53.
    Valente LJ; Grabow S; Vandenberg CJ; Strasser A; Janic A
    Oncogene; 2016 Jul; 35(29):3866-71. PubMed ID: 26640149
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.